{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:37:12Z","timestamp":1787582232235,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The LENAddOn study aimed to characterize people with HIV (PWH) initiating injectable lenacapavir (LEN) post-early access program in France, assess LEN continuation rates at W26 and W52, and describe reasons for LEN discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational, retrospective study across 19 centers, including people with HIV-1 who initiated LEN between 20 June 2023 and 30 June 2024. Sociodemographic, clinical, and laboratory data were extracted from medical records. The primary outcome was the proportion of PWH receiving a second and third set of LEN injections at W26 and W52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-seven PWH were included (median age, 57 years [IQR, 44\u201363]; duration of antiretroviral therapy (ART), 25 years [17\u201329]), with a history of frequent adherence issues and vulnerability factors. At LEN initiation, 22 (28.6%) had a plasma HIV-1 viral load (pVL) \u2265200\u2005copies\/mL, and 43 (55.8%) had a pVL &amp;lt;50\u2005copies\/mL; 42 (54.6%) had viral resistance to \u22652 drugs in \u22653 classes. Twenty-one participants (27.3%) received injectable ART associating LEN plus cabotegravir \u00b1 rilpivirine. Lenacapavir continuation rate was 94.8% (95% CI, 87.2\u201398.6) at W26 and 81.8% (71.4\u201389.7) at W52, with 4 LEN discontinuations between D0 and W26 and 10 between W26 and W52. Main reasons for LEN discontinuation were death unrelated to LEN\/lost-to-follow-up (n = 5), persistence of viral replication (n = 3), and injection site reactions (n = 2). Last measured pVL during the study period was &amp;lt;200 cp\/mL in 72\/77 participants (93.5%) and &amp;lt;50 cp\/mL in 61\/77 (79.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lenacapavir use allowed simplification of antiretroviral regimens, with the maintenance or achievement of virological suppression. Continuation of LEN at W26 and W52 remained high among a population with extensive treatment history.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag512","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:47:19Z","timestamp":1786798039000},"source":"Crossref","is-referenced-by-count":0,"title":["Lenacapavir Use in France: A National, Observational Study (LENAddOn)"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"first","affiliation":[{"name":"Paris Cit\u00e9 University, Inserm, IAME, Infectious Diseases Department, Bichat-Claude Bernard Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-1480","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[{"name":"Sorbonne University, Inserm, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-1270","authenticated-orcid":false,"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[{"name":"Nantes University, Inserm 1413, Nantes University Hospital , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-4822","authenticated-orcid":false,"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Orl\u00e9ans University Hospital , Orl\u00e9ans ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Sorbonne University, Inserm, Pierre Louis Epidemiology and Public Health Institute (iPLESP), Infectious Diseases Department, Saint-Antoine Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cua","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Nice University Hospital , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-4178","authenticated-orcid":false,"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Bordeaux University, Inserm 1219, BPH , Infectious Diseases Department, Saint-Andr\u00e9 Hospital, Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-4173","authenticated-orcid":false,"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, IHU Imagine, Necker-Pasteur Infectiology Center, Infectious Diseases Department, Necker Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-8444","authenticated-orcid":false,"given":"Alain","family":"Makinson","sequence":"additional","affiliation":[{"name":"Montpellier University, Inserm 1175, Infectious Diseases Department, Montpellier University Hospital , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jacomet","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Clermont-Ferrand University Hospital , Clermont-Ferrand ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lascoux","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, Infectious Diseases Department, Saint-Louis University Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Viard","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, Inserm, Cochin Institute, Immunology and Infectious Diseases Department, H\u00f4tel-Dieu Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Robineau","sequence":"additional","affiliation":[{"name":"Lille University, EA2694, Infectious Diseases Department, Tourcoing Hospital , Tourcoing ,","place":["France"]},{"name":"Sorbonne University, Inserm, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-9420","authenticated-orcid":false,"given":"Maxime","family":"Hentzien","sequence":"additional","affiliation":[{"name":"Reims Champagne-Ardenne University, VieFra , Internal Medicine, Infectious Diseases and Clinical Immunology Department, Reims University Hospital, Reims ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Teicher","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Bic\u00eatre University Hospital, AP-HP , Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[{"name":"Sorbonne University, Inserm, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Infectious Diseases Department, Tenon Hospital, AP-HP, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Abgrall","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Antoine-B\u00e9cl\u00e8re University Hospital, AP-HP , Clamart ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cazanave","sequence":"additional","affiliation":[{"name":"Bordeaux University, CNRS UMR 5234 MFP, ARMYNE Team , Infectious and Tropical Diseases Department, Pellegrin Hospital, Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Cabi\u00e9","sequence":"additional","affiliation":[{"name":"Antilles University, Caribbean Clinical Investigation Center, Montpellier University, Inserm CIC2504, PCCEI , Infectious Diseases Department, Fort-de-France University Hospital, Fort-de-France, Martinique ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Dudoit","sequence":"additional","affiliation":[{"name":"Sorbonne University, Inserm, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University and Sorbonne Paris Nord University, Inserm, IAME, Pharmacology Department, Bichat-Claude Bernard Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4776-4827","authenticated-orcid":false,"given":"Guillaume","family":"Barri\u00e8re","sequence":"additional","affiliation":[{"name":"Gilead Sciences SAS , La D\u00e9fense ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9904-7186","authenticated-orcid":false,"given":"Keith","family":"Dunn","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. , Foster City ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-8999","authenticated-orcid":false,"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne University, Inserm, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Sorbonne University, Inserm, Pierre Louis Epidemiology and Public Health Institute (iPLESP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0101","authenticated-orcid":false,"given":"Romain","family":"Palich","sequence":"additional","affiliation":[{"name":"Paris Cit\u00e9 University, Inserm, CRESS, Immunology and Infectious Diseases Department, H\u00f4tel-Dieu Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the LENAddOn Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Perreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Delaune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Krzyzanowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Cros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Richier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"de Dieuleveult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Goujard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Quertainmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Godard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Proux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bachelard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00e9lie","family":"Julia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racha","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awa","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Cabras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorry","family":"Facelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouz\u00e9","family":"Bani-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kmiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiem","family":"Loghmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Le Baut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morane","family":"Cavallec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soria","family":"Albane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto Paredes","family":"Manyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Breaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Touitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Siguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christia","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouniya","family":"Mebarki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Adda-Lievin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Coban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Baclet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Cornavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Viget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Marien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Louisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete Gomes","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Laradh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Ouazene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Zemouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lamarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikrame","family":"Benyamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afiya","family":"Nadour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efma","family":"Hamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malikhone","family":"Chansombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026082409563210000_ofag512-B1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/87551225241259894","article-title":"A narrative review of novel agents for managing heavily treatment-experienced people living with HIV","volume":"40","author":"Beran","year":"2024","journal-title":"J Pharm Technol"},{"key":"2026082409563210000_ofag512-B2","doi-asserted-by":"crossref","first-page":"3000605241301883","DOI":"10.1177\/03000605241301883","article-title":"Heavily treatment-experienced patients with HIV: are new mechanisms of action enough?","volume":"52","author":"Brizzi","year":"2024","journal-title":"J Int Med Res"},{"key":"2026082409563210000_ofag512-B3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/dkm522","article-title":"What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?","volume":"61","author":"Grover","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2026082409563210000_ofag512-B4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"2026082409563210000_ofag512-B5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2026082409563210000_ofag512-B6","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jac\/dkaa060","article-title":"Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients","volume":"75","author":"Marcelin","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026082409563210000_ofag512-B7","doi-asserted-by":"crossref","first-page":"e02057","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026082409563210000_ofag512-B8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082409563210000_ofag512-B9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciae423","article-title":"Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multidrug-resistant HIV-1: week 104 results of a phase 2\/3 trial","volume":"80","author":"Ogbuagu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026082409563210000_ofag512-B10","author":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM)"},{"key":"2026082409563210000_ofag512-B11","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1038\/s41598-021-88367-5","article-title":"Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss","volume":"11","author":"Mussini","year":"2021","journal-title":"Sci Rep"},{"key":"2026082409563210000_ofag512-B12","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1186\/s12889-025-25565-0","article-title":"Factors associated with loss to follow-up among people living with HIV at public health facilities in Manaus, Brazil: a multicentric study","volume":"25","author":"Salimo","year":"2025","journal-title":"BMC Public Health"},{"key":"2026082409563210000_ofag512-B13","first-page":"100207","article-title":"A qualitative inquiry into the patient-related barriers to linkage and retention in HIV care within the community setting","volume":"9","author":"Tarfa","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"key":"2026082409563210000_ofag512-B14","doi-asserted-by":"crossref","first-page":"e3361","DOI":"10.1097\/MD.0000000000003361","article-title":"Adherence to antiretroviral therapy and virologic failure: a meta-analysis","volume":"95","author":"Bezabhe","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026082409563210000_ofag512-B15","doi-asserted-by":"crossref","first-page":"19533","DOI":"10.7448\/IAS.17.4.19533","article-title":"Socio-economic factors and virological suppression among people diagnosed with HIV in the United Kingdom: results from the ASTRA study","volume":"17","author":"Burch","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2026082409563210000_ofag512-B16","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/QAD.0000000000001068","article-title":"Socioeconomic status and response to antiretroviral therapy in high-income countries: a literature review","volume":"30","author":"Burch","year":"2016","journal-title":"AIDS"},{"key":"2026082409563210000_ofag512-B17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082409563210000_ofag512-B18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082409563210000_ofag512-B19","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2026082409563210000_ofag512-B20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2026082409563210000_ofag512-B21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026082409563210000_ofag512-B22","doi-asserted-by":"crossref","first-page":"ofae125","DOI":"10.1093\/ofid\/ofae125","article-title":"Case series of people with HIV on the long-acting combination of lenacapavir and cabotegravir: call for a trial","volume":"11","author":"Gandhi","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026082409563210000_ofag512-B23","doi-asserted-by":"crossref","first-page":"ofaf615","DOI":"10.1093\/ofid\/ofaf615","article-title":"Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in people with HIV-1 who are virologically suppressed on complex antiretroviral regimens at baseline","volume":"12","author":"Mounzer","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026082409563210000_ofag512-B24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/ANNALS-25-01939","article-title":"Once-weekly oral islatravir plus lenacapavir versus daily oral bictegravir, emtricitabine, and tenofovir alafenamide in persons with HIV-1: a phase 2 randomized study","volume":"179","author":"Colson","year":"2026","journal-title":"Ann Intern Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag512\/70702882\/ofag512.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag512\/70702882\/ofag512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag512\/70702882\/ofag512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:56:39Z","timestamp":1787579799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag512\/8765657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag512","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]},"article-number":"ofag512"}}